A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Part of paid clinical trials in Chino, California.
- Sponsor
- Seaport Therapeutics
- Study ID
- NCT07065240
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Major Depressive Disorder (MDD)
- Major Depressive Disorder With Anxious Distress
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- SPT-300 — DRUGA prodrug of allopregnanolone, a small molecule drug
- Placebo — DRUGPlacebo for SPT-300
Study Details
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.
Key Dates
- Start date
- Jun 19, 2025
- Status verified
- May 2026
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 360 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: SPT-300Participants will receive SPT-300 capsules once daily for 42 days
- Placebo Comparator: PlaceboParticipants will receive matching placebo once daily for 42 days
Primary Outcome Measure
Change From Baseline to Day 42 in Hamilton Depression Rating Scale-17 (HAM-D-17) Total Score [ Time Frame: Baseline (Day 0) to Day 42 ]
Central Contacts
- Clinical trial information desk617-807-4062
Locations (28)
Find similar trials in Chino, CA
Related Studies
- Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic PsychedelicsRecruiting · Yale University · Hamden, Connecticut
- Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of KetamineEARLY_PHASE1 · Recruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderPHASE3 · Recruiting · Cybin IRL Limited · Birmingham, Alabama
- Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderPHASE3 · Recruiting · Vanda Pharmaceuticals · Phoenix, Arizona